- ISIN
- US10806X1028
- CUSIP
- 10806X102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 27, 2019
Highlights
- Market Cap
- $13.37B
- Enterprise Value
- $12.53B
- EPS (TTM)
- -$3.76
- Total Revenue (TTM)
- $566.04M
- Gross Profit (TTM)
- $538.20M
- EBITDA (TTM)
- -$602.24M
- Year Range
- $41.80 - $84.94
- Target Price
- $100.58
- ROA (TTM)
- -52.95%
- ROE (TTM)
- 32.00%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BBIO Performance Chart
BridgeBio Pharma, Inc. (BBIO) is down 10.3% since the beginning of the year. At $69 per share, BBIO is trading 19.2% below its 52-week high of $85. Investors who bought $1,000 worth of BBIO shares 5 years ago would now be looking at an investment worth $1,154.
Loading charts...
Returns By Period
BridgeBio Pharma, Inc. (BBIO) has returned -10.28% so far this year and 62.73% over the past 12 months.
BridgeBio Pharma, Inc.
- 1D
- -0.42%
- 1M
- -0.71%
- YTD
- -10.28%
- 6M
- -10.17%
- 1Y
- 62.73%
- 3Y*
- 63.65%
- 5Y*
- 2.90%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
BBIO Monthly Returns History
Based on dividend-adjusted daily data since Jun 27, 2019, BBIO's average daily return is +0.19%, while the average monthly return is +3.02%. At this rate, an investment would double in approximately 1.9 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jul 2023 with a return of +103.6%, while the worst month was Dec 2021 at -58.8%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 4 months.
On a daily basis, BBIO closed higher 49% of trading days. The best single day was Jul 17, 2023 with a return of +75.9%, while the worst single day was Dec 27, 2021 at -72.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.02% | -13.96% | 11.70% | -4.24% | -6.82% | 3.58% | -10.28% | ||||||
| 2025 | 24.67% | 2.02% | -0.95% | 10.96% | -10.71% | 26.07% | 9.47% | 9.50% | 0.35% | 20.60% | 14.96% | 6.22% | 178.75% |
| 2024 | -15.06% | -0.41% | -9.46% | -17.14% | 9.33% | -9.57% | 2.45% | 7.32% | -8.58% | -8.05% | 15.72% | 1.29% | -32.03% |
| 2023 | 21.78% | 23.06% | 45.18% | -12.42% | -5.51% | 25.36% | 103.55% | -14.57% | -11.84% | -1.25% | 10.25% | 40.61% | 429.79% |
| 2022 | -40.83% | -20.97% | 30.13% | -20.99% | -14.84% | 32.94% | -4.63% | 21.25% | -5.33% | 4.93% | -10.16% | -18.68% | -54.32% |
| 2021 | -20.18% | 24.52% | -12.85% | -9.22% | 5.87% | 2.97% | -12.32% | -6.25% | -6.47% | 5.36% | -17.98% | -58.81% | -76.54% |
Benchmark Metrics
BridgeBio Pharma, Inc. has an annualized alpha of 32.62%, beta of 1.33, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since June 27, 2019.
- This stock participated in 108.55% of S&P 500 Index downside but only 101.00% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 32.62%
- Beta
- 1.33
- R²
- 0.10
- Upside Capture
- 101.00%
- Downside Capture
- 108.55%
Return for Risk
Risk / Return Rank
BBIO ranks 80 for risk / return — in the top 80% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBIO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.42 | ||
| Sortino ratioReturn per unit of downside risk | -0.41 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.32 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 3.11 | 2.46 | +0.66 |
| Martin ratioReturn relative to average drawdown | 7.28 | 10.92 | -3.64 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BridgeBio Pharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BridgeBio Pharma, Inc. was 92.80%, occurring on May 11, 2022. Recovery took 894 trading sessions.
The current BridgeBio Pharma, Inc. drawdown is 14.12%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -92.80%May 2022 | 1y 3mo | 3y 6mo | 4y 9moFeb 2021 - Dec 2025 |
COVID crash2020 | -65.45%Mar 2020 | 2mo 25d | 8mo 11d | 11mo 6dDec 2019 - Nov 2020 |
2019 bear market2019 | -44.53%Oct 2019 | 1mo 12d | 1mo 5d | 2mo 17dSep 2019 - Nov 2019 |
2021 bear market2021 | -21.99%Jan 2021 | 23d | 12d | 1mo 5dJan 2021 - Feb 2021 |
2026 bear market2026 | -20.25%Feb 2026 | 13d | — | 5mo 2dJan 2026 - now |
Drawdown Indicators
| BBIO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.80% | -56.78% | -36.02% |
Max Drawdown (1Y)Largest decline over 1 year | -20.25% | -9.10% | -11.15% |
Max Drawdown (3Y)Largest decline over 3 years | -49.08% | -18.90% | -30.18% |
Max Drawdown (5Y)Largest decline over 5 years | -91.89% | -25.43% | -66.46% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -14.12% | -3.21% | -10.91% |
Average DrawdownAverage peak-to-trough decline | -45.66% | -10.71% | -34.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.64% | 2.04% | +6.60% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BridgeBio Pharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BridgeBio Pharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BBIO relative to other companies in the Biotechnology industry. Currently, BBIO has a P/S ratio of 23.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BBIO
Add BridgeBio Pharma, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BBIO